Status:
COMPLETED
Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy
Lead Sponsor:
Puerta de Hierro University Hospital
Conditions:
Cardiac Allograft Vasculopathy
Eligibility:
All Genders
18-80 years
Brief Summary
Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-d...
Eligibility Criteria
Inclusion
- Patients over 18 and under 80 years old, HT \> 1 year ago
Exclusion
- Patients under 18 or over 80 years old
- Multiorgan transplant
- History of acute cellular rejection ≥ 1R or antibody mediated rejection in the previous 6 months
- Concomitant infection by CMV
Key Trial Info
Start Date :
January 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2021
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04791852
Start Date
January 10 2019
End Date
April 15 2021
Last Update
September 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Puerta de Hierro
Majadahonda, Madrid, Spain, 28222